A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

This Phase 2 study is testing whether a drug called pacritinib can safely and effectively treat Waldenström macroglobulinemia — a rare type of slow-growing blood cancer — in patients whose cancer came back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of Waldenström macroglobulinemia - Your cancer has returned or stopped responding to prior treatment - You have symptoms requiring treatment (e.g., fatigue, night sweats, low blood counts, swollen lymph nodes, or other complications) - Your IgM protein level is at least twice the upper limit of normal - Your overall health and organ function meet study requirements **You may NOT be eligible if...** - You have not had prior treatment, or your disease is not yet symptomatic - Your organ function does not meet minimum requirements - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.